Five-year cure of cervical cancer treated using californium-252 neutron brachytherapy.
Female pelvic carcinoma is one of the common malignancies seen at the University of Kentucky Medical Center and often presents in an advanced stage. In 1976, we began to test californium-252 neutron brachytherapy (NT) for its efficacy for control of primary and recurrent advanced uterine, cervix, and vaginal cancers. The first protocol used was 5000-5500 rad of whole pelvis irradiation followed by 1-2 Cf-252 insertions using a single tandem placed in the utero-cervico-vaginal region. Of 27 patients with primary carcinomas treated, 10 are alive and well 5 years later (37%). Two of two recurrent tumors were locally controlled but failed later. These patients had advanced cervical, vaginal, or endometrial carcinomas. In 1977, a transitional year, treatment of only unfavorable stages and presentations with NT was initiated. Similar results were obtained with NT as compared to conventional photon therapy (PT). Further improvement in treatment results can be anticipated as NT brachytherapy is used for advanced cancer therapy by more effective treatment schedules and radiation doses. Cf-252 can be used as a radium substitute and achieved similar rates of tumor control and 5-year survivals.
D000230:Adenocarcinoma / Q000532:radiotherapy; D001918:Brachytherapy / Q000009:adverse effects; D002142:Californium / Q000627:therapeutic use*; D002588:Cesium Radioisotopes / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy*; D014594:Uterine Neoplasms / Q000532:radiotherapy
D002588:Cesium Radioisotopes; D002142:Californium